FRI0458\u2005OBJECTIVE MEASURES OF PSORIASIS SEVERITY AND THE RISK FOR PSA: RESULTS FROM THE INCIDENT HEALTH OUTCOMES AND PSORIASIS EVENTS PROSPECTIVE COHORT STUDY

Abstract

Background Psoriasis severity is a presumed risk factor for development of psoriatic arthritis (PsA) but most studies have examined this question retrospectively. Additionally, it remains unclear whether obesity and body surface area of psoriasis (BSA) are independent risk factors for PsA. Objectives We examined the association of psoriasis severity, obesity and other potential risk factors for the development of PsA in patients with psoriasis. Methods Between 2008-2011, patients with at least one code for psoriasis aged 25-60 years in The Health Improvement Network were randomly selected and questionnaires were sent to their general practitioners (GPs). GPs were asked to confirm the diagnosis of psoriasis and provide the patient’s approximate BSA that the patient typically demonstrates based on categories commonly used for epidemiological studies. Data through 2015 were used in the current analysis. After excluding patients with PsA at baseline, the incidence of PsA among patients with psoriasis was calculated. Cox proportional hazard ratios were used to examine the risk of developing PsA among patients with mild (<3%), moderate (3-10%) and severe (>10%) psoriasis. We also examined other covariates including obesity, depression, recent infections, smoking, and comorbidities in univariable models. Factors significant at the unviariable level were included in multivariable models. We additionally tested an interaction between BSA and obesity. Results Among 10,474 questionnaires sent, 9,987 (95%) were returned and, of those, 9,069 (91%) had confirmed psoriasis. The mean age was 46 and 53% were female. BSA was provided for 8,881 patients of which 52% had mild psoriasis, 36% moderate psoriasis, and 12% severe psoriasis. Mean follow up time was 4.2 years (SD 2.1); the incidence of PsA was 5.4 cases per 1,000 person years. In univariable models, age and sex were not associated with PsA but obesity, BMI (continuous), BSA (continuous and category) and depression were significantly associated with development of PsA. The final multivariable model included BSA category (ref mild, moderate: HR 1.44, 95%CI: 1.02-2.03; severe HR 1.99, 1.28-3.11), history of depression (1.69, 1.22-2.34), obesity (1.64, 1.19-2.25), age (HR 0.99, 0.98-1.00) and female sex (HR 0.72, 0.52-0.99). There was not a statistically significant interaction between BSA and obesity although patients that were obese and had ≥10% BSA had the highest risk (HR 3.90, 2.22-6.85). Conclusion In this large prospective cohort study, we found that body surface area is a strong predictor of developing psoriasis over the next 4-7 years and obesity is an additive risk factor. References [1] Scher JU, et al. Nat Rev Rheumatol2019In Press. Acknowledgement Funded by NIH/NIAMS K23 AR063764 Disclosure of Interests Alexis Ogdie Grant/research support from: (To my university) Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly and Company, Novartis, Pfizer, and Takeda, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Daniel Shin: None declared, Hyon Choi: None declared, Christopher T. Ritchlin Grant/research support from: AbbVie, Amgen, UCB Pharma, Consultant for: AbbVie, Amgen, Lilly, Novartis, Pfizer, UCB Pharma, Joseph F. Merola Consultant for: Biogen IDEC, Abbvie, Amgen, Eli Lilly and Company, Novartis, Pfizer, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, Merck, and GSK, Jose Scher Grant/research support from: Pfizer, Novartis, Consultant for: Janssen, UCB, Novartis, Amgen, Thorvardur Jon Love Consultant for: Received reimbursment from Celgene for speaking about guidelines for the treatment of psoriatic arthritis, Joel Gelfand Grant/research support from: Research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Boehringer Ingelheim, Janssen, Novartis Corp, Celgene, Ortho Dermatologics, and Pfizer Inc., Consultant for: BMS, Boehringer Ingelheim, Janssen Biologics, Novartis Corp, UCB (DSMB), Sanofi, and Pfizer Inc., Paid instructor for: Received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologics and Novartis. Univariable Multivariable HR (95% CI) HR (95% CI) Age 0.99 (0.98-1.00) 0.99 (0.98-1.00) Female Sex 0.83 (0.63-1.09) 0.72 (0.52-0.99) Body Mass Index (per 1 unit) 1.04 (1.02-1.07) Obese BMI (BMI>30 vs <=30) 1.62 (1.20-2.17) 1.64 (1.19-2.25) Smoking Never Ref Current 0.90 (0.64-1.27) Past 1.30 (0.95-1.79) Body Surface Area Category Mild (<3) Ref Moderate (3-10) 1.55 (1.13-2.14) 1.44 (1.02-2.03) Severe (>10) 2.40 (1.60-3.59) 1.99 (1.28-3.11) Anxiety 0.94 (0.67-1.32) Depression 1.45 (1.09-1.92) 1.69 (1.22-2.34) Any diarrheal illness 1.28 (0.93-1.75) Disabled 1.41 (0.75-2.67) Prior light therapy 2.29 (1.33-3.93) Hyperlipidemia 0.94 (0.60-1.48) Hypertension 1.04 (0.72-1.49) Diabetes 0.72 (0.40-1.30)